Morolimumab
Morolimumab
Morolimumab (pronunciation: mo-ro-li-mu-mab) is a monoclonal antibody designed for the treatment of various autoimmune diseases. It is a type of biologic therapy that targets and neutralizes specific proteins in the body that contribute to the development and progression of autoimmune conditions.
Etymology
The name "Morolimumab" is derived from the International Nonproprietary Names (INN) system for pharmaceutical substances. The "-mab" suffix indicates that it is a monoclonal antibody, while the prefix "Moroli-" does not have a specific meaning and is used for unique identification.
Mechanism of Action
Morolimumab works by binding to specific proteins in the body that are involved in the immune response. By blocking these proteins, it can help to reduce inflammation and slow the progression of autoimmune diseases.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Autoimmune disease: A condition in which your immune system mistakenly attacks your body.
- Biologic therapy: Treatment that uses your body's own immune system to fight cancer.
- Inflammation: A localized physical condition in which part of the body becomes reddened, swollen, hot, and often painful, especially as a reaction to injury or infection.
See Also
External links
- Medical encyclopedia article on Morolimumab
- Wikipedia's article - Morolimumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski